Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to 0.65%.

  • ImmunityBio's Return on Capital Employed rose 4000.0% to 0.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.65%, marking a year-over-year increase of 4000.0%. This contributed to the annual value of 0.89% for FY2024, which is 800.0% up from last year.
  • As of Q3 2025, ImmunityBio's Return on Capital Employed stood at 0.65%, which was up 4000.0% from 0.94% recorded in Q2 2025.
  • ImmunityBio's Return on Capital Employed's 5-year high stood at 14.9% during Q2 2022, with a 5-year trough of 7.05% in Q1 2022.
  • In the last 5 years, ImmunityBio's Return on Capital Employed had a median value of 1.0% in 2024 and averaged 0.53%.
  • As far as peak fluctuations go, ImmunityBio's Return on Capital Employed soared by 166500bps in 2022, and later tumbled by -136400bps in 2023.
  • ImmunityBio's Return on Capital Employed (Quarter) stood at 12.09% in 2021, then tumbled by -80bps to 2.45% in 2022, then plummeted by -136bps to 0.88% in 2023, then dropped by -22bps to 1.08% in 2024, then skyrocketed by 40bps to 0.65% in 2025.
  • Its last three reported values are 0.65% in Q3 2025, 0.94% for Q2 2025, and 1.07% during Q1 2025.